sickle cell disease

Ann Thompson / WVXU

Increasingly, sickle cell anemia patients in the U.S. are moving away from blood transfusions and instead using a medicine called Hydroxyurea to control their disease and eliminate the symptoms. Cincinnati Children's Hospital Medical Center researchers are perfecting a technique that determines the correct dosage for each patient in one day.

sickle cell injection
Dick Whipple / AP

Cincinnati Children's is partnering with the Swiss company Roivant on a new venture called Aruvant Sciences, a biopharmaceutical company focusing on innovative gene therapies for hematological conditions such as sickle cell disease. Terms of the deal aren't disclosed in the news release, however, the Cincinnati Business Courier reports it's the hospital's biggest commercialization deal ever.